Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Hepatitis B 9Carcinoma, Hepatocellular 9Lymphoma, Non-Hodgkin 3Lymphoma 3Stomach Neoplasms 1Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Liver Neoplasms 1Hepatitis B, Chronic 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Adalimumab 13Methotrexate 11Etanercept 10Rituximab 5Abatacept 5tocilizumab 4olokizumab 4tofacitinib 3golimumab 3Infliximab 3Tumor Necrosis Factor Inhibitors 2Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2Certolizumab Pegol 2Antirheumatic Agents 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Arthritis, Rheumatoid × entecavir × Clear all
NCT01907230 2019-03-13

Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients

Taipei Veterans General Hospital, Taiwan

Phase 4 Unknown
115 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡